The Memorial Sloan Kettering Cancer Center (MSK) will be collaborating with Absci Corporation to discover and develop novel cancer therapeutics using generative artificial intelligence (AI) for up to six programmes.

Under the terms of the collaboration, Absci and MSK’s cancer research teams will co-develop therapeutics using Absci’s platform.

“At MSK, we are committed to continuous innovation as we strive toward our mission of ending cancer for life, and we expect cancer care AI to play an increasingly important role,” said Gregory Raskin, Senior Vice President of Technology Development at MSK.  “We look forward to collaborating with Absci in leveraging the company’s generative AI platform in our ongoing efforts to advance cancer research and develop new therapies for our patients.”

Over the last year, Absci has joined forces with various pharma companies and research institutes, including AstraZeneca and Almirall, alongside existing collaborations with Merck, NVIDIA and others.

In addition to drug creation partnerships, Absci continues to develop a pipeline of internal drug candidates, including ABS-101, a potential best-in-class anti-TL1A antibody, designed and optimised using generative AI.

“MSK has an incredible record of groundbreaking translational and clinical innovations in oncology,” said Sean McClain, Founder & CEO of Absci. “By combining MSK’s research expertise with our generative AI drug creation platform, we have the potential to unlock critical advances toward treating this devastating disease.”

Read the DDW interview with Sean McClain, Founder & CEO of Absci.